These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 89511)

  • 61. Low-potency oestrogen and risk of endometrial cancer: a case-control study.
    Weiderpass E; Baron JA; Adami HO; Magnusson C; Lindgren A; Bergström R; Correia N; Persson I
    Lancet; 1999 May; 353(9167):1824-8. PubMed ID: 10359406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
    Beresford SA; Weiss NS; Voigt LF; McKnight B
    Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Estrogens: do the risks outweight the benefits?
    Rust JA; Langley II; Hill EC; Lamb EJ
    Am J Obstet Gynecol; 1977 Jun; 128(4):431-9. PubMed ID: 194481
    [No Abstract]   [Full Text] [Related]  

  • 64. Clinical use of progestins in the menopausal patient: dosage and duration.
    Gambrell RD
    J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy. A follow up study].
    Ulrich LS; Wells M; Sturdee DW; Barlow DH; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    Ugeskr Laeger; 2003 Sep; 165(37):3530-2. PubMed ID: 14531356
    [No Abstract]   [Full Text] [Related]  

  • 66. Estrogen regimen of women with endometrial carcinoma. A retrospective case-control study at Radiumhemmet.
    Obrink A; Bunne G; Collén J; Tjernberg B
    Acta Obstet Gynecol Scand; 1981; 60(2):191-7. PubMed ID: 7246086
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endometrial carcinogenesis and its relation to oestrogens.
    Fox H
    Pathol Res Pract; 1984 Sep; 179(1):13-9. PubMed ID: 6390390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical considerations in the management of the menopause: the endometrium.
    Whitehead MI; McQueen J; Minardi J; Campbell S
    Postgrad Med J; 1978; 54 Suppl 2():69-73. PubMed ID: 740583
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Therapy with gestagens in hyperplastic changes of the endometrium].
    Griesinger R; Schindler AE
    Geburtshilfe Frauenheilkd; 1986 Oct; 46(10):690-2. PubMed ID: 2948865
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oestrogen replacement therapy.
    Greenblatt RB; Gambrell RD
    Lancet; 1979 Jun; 1(8131):1398. PubMed ID: 87848
    [No Abstract]   [Full Text] [Related]  

  • 71. Testosterone and 17 beta-oestradiol secretion of the human ovary. II. normal postmenopausal women, postmenopausal women with endometrial hyperplasia and postmenopausal women with adenocarcinoma of the endometrium.
    Botella-Llusiá J; Oriol-Bosch A; Sánchez-Garrido F; Tresguerres JA
    Maturitas; 1980 Jan; 2(1):7-12. PubMed ID: 7402088
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy.
    Kauppila A; Kivinen S; Leinonen P; Tuimala R; Vihko R; Ylöstalo P
    Arch Gynecol; 1983; 234(1):49-58. PubMed ID: 6660928
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hormone replacement therapy and endometrial carcinoma.
    Mack TM; Pike MC
    Lancet; 1977 Jun; 1(8026):1358. PubMed ID: 69069
    [No Abstract]   [Full Text] [Related]  

  • 74. A review of study findings of the risks and benefits of oestrogen therapy in the female climacteric.
    Rauramo L
    Maturitas; 1986 Oct; 8(3):177-87. PubMed ID: 3537634
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alterations in carbohydrate metabolism induced by progesterone in cases of endometrial carcinoma and hyperplasia.
    Benjamin F; Casper DJ
    Am J Obstet Gynecol; 1966 Apr; 94(7):991-6. PubMed ID: 5910367
    [No Abstract]   [Full Text] [Related]  

  • 76. P53 expression in spontaneous and estradiol-induced endometrial hyperplasia during menopause.
    Maia H; Maltez A; Athayde C; Coelho G; Coutinho EM
    Maturitas; 2003 Mar; 44(3):175-80. PubMed ID: 12648880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy.
    von Dadelszen P; Gillmer MD; Gray MD; McEwan HP; Pyper RJ; Rollason TP; Wright A
    Br J Obstet Gynaecol; 1994 Feb; 101(2):158-61. PubMed ID: 8305393
    [No Abstract]   [Full Text] [Related]  

  • 78. Hormonal replacement therapy: benefits, risks, doses.
    Huppert LC
    Med Clin North Am; 1987 Jan; 71(1):23-39. PubMed ID: 3543541
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Endometrial carcinoma after Hodgkin disease in childhood.
    Brown G; Li FP; Cohen H; Cassady JR; Goldstein D
    Med Pediatr Oncol; 1980; 8(2):205-7. PubMed ID: 7421734
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma.
    Baker VV
    J Cell Biochem Suppl; 1995; 23():184-8. PubMed ID: 8747395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.